Biotec begins phase 2 study of SBG in treatment of diabetic foot ulcers

By Lisa Kerner

Erie, Pa., Feb. 24 - Biotec Pharmacon said it has entered into an agreement with Nottingham City Hospital NHS Trust to perform a clinical phase 2 study to determine the efficacy of soluble beta-1,3/1,6-glucan (SBG) in chronic foot ulcers in diabetic patients.

The randomized, double-blind, placebo-controlled study of 104 patients is expected to begin during the first half of 2006, pending regulatory approvals.

Biotec is performing a similar study in Russia, based on results from a pilot study of SBG on patients with diabetic ulcers.

SBG binds to and activates immune cells in skin to promote healing of wounds and ulcers, according to a company news release.

Biotec, based in Oslo, Norway, develops products for immune-related diseases.

Nottingham City Hospital NHS Trust is engaged in clinical research and the diagnosis, treatment and prevention of disease, particularly diabetes.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.